# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price target.
This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adu...
Barrington Research analyst Michael Petusky reiterates Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price tar...
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.94 by 10....
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share ...
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target f...
Haemonetics (NYSE:HAE) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.89 by 11....